Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 958-967

  Van Vollenhoven, Ronald F ^a   Mosca, Marta ^b   Bertsias, George ^c   Isenberg, David ^d   Kuhn, Annegret ^e   Lerstrøm, Kirsten ^f   Aringer, Martin ^g   Bootsma, Hendrika ^h   Boumpas, Dimitrios ^c   Bruce, Ian N ⁱ   Cervera, Ricard ^j   Clarke, Ann ^k   Costedoat Chalumeau, Nathalie ^l   Czirják, László ^m   Derksen, Ronald ⁿ   Dörner, Thomas ^o   Gordon, Caroline ^p   Graninger, Winfried ^q   Houssiau, Frédéric ^r   Inanc, Murat ^s   Jacobsen, Søren ^t   Jayne, David ^u   Jedryka Goral, Anna ^v   Levitsky, Adrian ^a   Levy, Roger ^w   Mariette, Xavier ^x   Morand, Eric ^y   Navarra, Sandra ^z   Neumann, Irmgard ^aa   Rahman, Anisur ^d   Rovenský, Jozef ^ab   Smolen, Josef ^ac   Vasconcelos, Carlos ^ad   Voskuyl, Alexandre ^ae   Voss, Anne ^af   Zakharova, Helena ^ag   Zoma, Asad ^ah   Schneider, Matthias ^ai   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF CRETE   (Greece)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f University of Muenster ^*  (United Kingdom)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j HOSPITAL CLÍNIC   (Spain)

^k MCGILL UNIVERSITY   (Canada)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m UNIVERSITY OF PÉCS   (Hungary)

ⁿ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^p UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^q MEDICAL UNIVERSITY OF GRAZ   (Austria)

^r UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^s ISTANBUL UNIVERSITY   (Turkey)

^t Rigshospitalet   (Denmark)

^u ADDENBROOKE S HOSPITAL   (United Kingdom)

^v INSTITUTE OF RHEUMATOLOGY   (Poland)

^w STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^x BICÊTRE HOSPITAL   (France)

^y MONASH UNIVERSITY   (Australia)

^z UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^aa WILHELMINEN HOSPITAL   (Austria)

^ab NATIONAL INSTITUTE OF RHEUMATIC DISEASES   (Slovakia)

^ac MEDICAL UNIVERSITY OF VIENNA   (Austria)

^ad HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^ae VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^af UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^ag A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^ah Lanarkshire Centre for East Kilbride   (United Kingdom)

^ai HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL RESEARCH; COMORBIDITY; DISEASE ACTIVITY; DISEASE CONTROL; DRUG TARGETING; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEDICAL EXPERT; MEDICAL SPECIALIST; ORGAN INJURY; PATIENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; TREAT TO TARGET; TREATMENT OUTCOME;

PATIENT PERSPECTIVE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT;

ADVISORY COMMITTEES; DISEASE MANAGEMENT; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATIENT CARE PLANNING; REMISSION INDUCTION; SECONDARY PREVENTION;

EID: 84899937611     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-205139     Document Type: Article

References (122)

1. Swales JD. Pharmacological treatment of hypertension. Lancet 1994;344: 380-5. (Pubitemid 24248212)
2. Eastman RC, Keen H. The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet 1997;350(Suppl 1):SI29-32. (Pubitemid 27303535)
3. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364: 263-9. (Pubitemid 38942816)
4. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66: 1443-9. (Pubitemid 350032650)
5. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353: 1568-73. (Pubitemid 29219206)
6. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69: 631-7.
7. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73: 6-16.
8. Nived O, Jonsen A, Bengtsson AA, et al. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002;29: 1398-400. (Pubitemid 34755603)
9. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003;12: 18-23.
10. Group OLoEW. OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/ index.aspx?o=5653. In: Group OLoEW, ed., 2011.
11. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69: 1269-74.
12. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39: 363-9. (Pubitemid 26085211)
13. Petri M, Purvey S, Fang H, et al. Predictors of organ damage in systemic lupus erythematosus: The Hopkins Lupus Cohort. Arthritis Rheum 2012;64: 4021-8.
14. Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003;30: 1977-82. (Pubitemid 37075547)
15. Andrade RM, Alarcon GS, Fernandez M, et al. Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum 2007;56: 622-30.
16. Lopez R, Davidson JE, Beeby MD, et al. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology (Oxford) 2012;51: 491-8.
17. Bertoli AM, Vila LM, Apte M, et al. Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual. Rheumatology (Oxford) 2007;46: 1471-6. (Pubitemid 47317097)
18. Stoll T, Sutcliffe N, Mach J, et al. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology (Oxford) 2004;43: 1039-44. (Pubitemid 39144453)
19. Andrade RM, Alarcon GS, Gonzalez LA, et al. Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 2008;67: 829-34. (Pubitemid 351829384)
20. Manger K, Manger B, Repp R, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002;61: 1065-70. (Pubitemid 35397352)
21. Arends S, Grootscholten C, Derksen RH, et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis 2012;71: 966-73.
22. Reich HN, Gladman DD, Urowitz MB, et al. Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int 2011;79: 914-20.
23. Tisseverasinghe A, Lim S, Greenwood C, et al. Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. Arthritis Rheum 2006;54: 2211-19. (Pubitemid 44051077)
24. Drenkard C, Villa AR, Garcia-Padilla C, et al. Remission of systematic lupus erythematosus. Medicine 1996;75: 88-98.
25. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19: 949-56.
26. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46: 995-1002. (Pubitemid 34303812)
27. Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50: 2559-68. (Pubitemid 39062717)
28. Moroni G, Quaglini S, Gravellone L, et al. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin Arthritis Rheum 2012;41: 642-51.
29. Morand E, Franklyn K, Lau CS, et al. Consensus Definition and Preliminary Validation of a Low Disease Activity State in Systemic Lupus Erythematosus. Poster, ACR Annual Congress, 2013.
30. Strand V, Gladman D, Isenberg D, et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26: 490-7. (Pubitemid 29066763)
31. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63: 3918-30.
32. Griffiths B, Emery P, Ryan V, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford) 2010;49: 723-32.
33. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus 2011;20: 709-16.
34. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377: 721-31.
35. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365: 1886-95.
36. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69: 2083-9.
37. Moroni G, Quaglini S, Gallelli B, et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007;22: 2531-9. (Pubitemid 47365517)
38. Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002;61: 1502-9. (Pubitemid 34304512)
39. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005;32: 1467-72. (Pubitemid 41113966)
40. Birnbaum J, Petri M, Thompson R, et al. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009;60: 3378-87.
41. Swaak AJ, Nossent JC, Bronsveld W, et al. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48: 447-54. (Pubitemid 19158930)
42. Bandeira M, Buratti S, Bartoli M, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006;15: 515-20. (Pubitemid 44289549)
43. Laustrup H, Voss A, Green A, et al. SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus 2010;19: 239-46.
44. Mok CC, Ho CT, Wong RW, et al. Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2003;30: 1513-19. (Pubitemid 36835448)
45. Ho A, Barr SG, Magder LS, et al. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44: 2350-7. (Pubitemid 32977503)
46. Ho A, Magder LS, Barr SG, et al. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44: 2342-9. (Pubitemid 32977502)
47. Mirzayan MJ, Schmidt RE, Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39: 1316-19. (Pubitemid 32045856)
48. Petri M, Singh S, Tesfasyone H, et al. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009;36: 2476-80.
49. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45: 359-66. (Pubitemid 16121710)
50. ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33: 634-43. (Pubitemid 20166564)
51. Ng KP, Manson JJ, Rahman A, et al. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006;55: 900-4. (Pubitemid 44917463)
52. Bijl M, Dijstelbloem HM, Oost WW, et al. IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2002;41: 62-7. (Pubitemid 34537922)
53. Birmingham DJ, Irshaid F, Nagaraja HN, et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010;19: 1272-80.
54. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345: 1595-9.
55. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54: 3623-32. (Pubitemid 44737174)
56. Steiman AJ, Gladman DD, Ibanez D, et al. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010;37: 1822-7.
57. Steiman AJ, Gladman DD, Ibanez D, et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res 2012;64: 511-18.
58. Chambers SA, Allen E, Rahman A, et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 2009;48: 673-5.
59. Hanly JG, Urowitz MB, Su L, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis 2012;71: 1502-9.
60. Mak A, Cheung MW, Chiew HJ, et al. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum 2012;41: 830-9.
61. Ramsey-Goldman R, Alarcon GS, McGwin G, et al. Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort. Lupus 2008;17: 177-84. (Pubitemid 351588939)
62. Dua AB, Touma Z, Toloza S, et al. Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Curr Rheumatol Rep 2013;15:380.
63. Kiani AN, Petri M. Quality-of-life measurements versus disease activity in systemic lupus erythematosus. Curr Rheumatol Rep 2010;12: 250-8.
64. Jolly M, Pickard AS, Wilke C, et al. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis 2010;69: 29-33.
65. McElhone K, Castelino M, Abbott J, et al. The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. J Rheumatol 2010;37: 2273-9.
66. Zhu TY, Tam LS, Lee VW, et al. Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J Rheumatol 2010;37: 568-73.
67. Aggarwal R, Wilke CT, Pickard AS, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol 2009;36: 1209-16.
68. Doria A, Rinaldi S, Ermani M, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford) 2004;43: 1580-6. (Pubitemid 39642587)
69. Yazdany J, Trupin L, Gansky SA, et al. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res 2011;63: 1170-7.
70. Appenzeller S, Clarke AE, Panopalis P, et al. The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol 2009;36: 947-52.
71. Kuriya B, Gladman DD, Ibanez D, et al. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008;59: 181-5. (Pubitemid 351272952)
72. Mok CC, Ho LY, Cheung MY, et al. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009;38: 121-7.
73. Moorthy LN, Peterson MG, Hassett AL, et al. Relationship between health-related quality of life and SLE activity and damage in children over time. Lupus 2009;18: 622-9.
74. Grootscholten C, Snoek FJ, Bijl M, et al. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/methylprednisolone in a randomized controlled trial. J Rheumatol 2007;34: 1699-707. (Pubitemid 47267613)
75. Strand V, Aranow C, Cardiel MH, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003;12: 677-86. (Pubitemid 37173664)
76. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71: 1343-9.
77. So MW, Koo BS, Kim YG, et al. Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis. Clin Rheumatol 2011;30: 1399-405.
78. Faurschou M, Dreyer L, Kamper AL, et al. Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010;62: 873-80.
79. Dall'era M, Stone D, Levesque V, et al. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res 2011;63: 351-7.
80. Esdaile JM, Levinton C, Federgreen W, et al. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 1989;72: 779-833. (Pubitemid 19230673)
81. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57: 258-64. (Pubitemid 30227773)
82. Jacobsen S, Starklint H, Petersen J, et al. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J Rheumatol 1999;28: 288-99. (Pubitemid 29491401)
83. Rzany B, Coresh J, Whelton PK, et al. Risk factors for hypercreatinemia in patients with systemic lupus erythematosus. Lupus 1999;8: 532-40. (Pubitemid 29452566)
84. Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol 1995;242: 326-31.
85. Lu X, Gu Y, Wang Y, et al. Prognostic factors of lupus myelopathy. Lupus 2008;17: 323-8. (Pubitemid 351655800)
86. Fernandes Moca Trevisani V, Castro AA, Ferreira Neves Neto J, et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2013;2: CD002265.
87. Henderson L, Masson P, Craig JC, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev 2012;12:CD002922.
88. Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340: 741-5.
89. Ginzler E, Sharon E, Diamond H, et al. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975; 18: 27-34.
90. Mok CC, Ying KY, Ng WL, et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355 e25-33.
91. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69: 61-4.
92. Laskari K, Tzioufas AG, Antoniou A, et al. Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. J Rheumatol 2011;38: 1304-8.
93. Yap DY, Ma MK, Mok MM, et al. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 2013;52: 480-6.
94. Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36: 560-4.
95. Rygg M, Pistorio A, Ravelli A, et al. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis 2012;71: 511-17.
96. Mazzantini M, Torre C, Miccoli M, et al. Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study. J Rheumatol 2012;39: 552-7.
97. Mazzantini M, Talarico R, Doveri M, et al. Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study. J Rheumatol 2010;37: 2232-6.
98. Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, et al. Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 2004;13: 900-5. (Pubitemid 39664947)
99. Mok MY, Chan EY, Fong DY, et al. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 2005;32: 622-8. (Pubitemid 40524692)
100. Tarr T, Lakos G, Bhattoa HP, et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007;16: 39-45. (Pubitemid 46174314)
101. Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet 2010;376: 1498-509.
102. Tektonidou MG, Laskari K, Panagiotakos DB, et al. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009;61: 29-36.
103. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349: 1133-8. (Pubitemid 37122325)
104. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3: 848-53. (Pubitemid 41632808)
105. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332: 993-7.
106. Tan BE, Thong BY, Shivananda S, et al. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus 2009;18: 752-8.
107. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69: 20-8.
108. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998;7: 80-5. (Pubitemid 28107971)
109. Bezerra EL, Vilar MJ, da Trindade Neto PB, et al. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52: 3073-8. (Pubitemid 41447088)
110. Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 2009;18: 735-9.
111. Fessler BJ, Alarcon GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52: 1473-80. (Pubitemid 40663939)
112. Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005;32: 824-7. (Pubitemid 40676490)
113. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15: 577-83. (Pubitemid 44661744)
114. Urowitz MB, Gladman DD, Tom BD, et al. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008;35: 2152-8.
115. Zheng ZH, Zhang LJ, Liu WX, et al. Predictors of survival in Chinese patients with lupus nephritis. Lupus 2012;21: 1049-56.
116. Duran-Barragan S, McGwin G Jr, Vila LM, et al. cohort LamU. Angiotensinconverting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) 2008;47: 1093-6. (Pubitemid 351865941)
117. McLaurin EY, Holliday SL, Williams P, et al. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005;64: 297-303.
118. Burgos PI, Vila LM, Reveille JD, et al. Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX). Lupus 2009;18: 1303-8.
119. Norby GE, Holme I, Fellstrom B, et al. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study. Arthritis Rheum 2009;60: 1060-4.
120. Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011;70: 760-5.
121. Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67: 330-4. (Pubitemid 351281266)
122. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62: 2458-66.